Arbor Biotechnologies Is A Biotechnology Company Located In Cambridgemassachusettsfounded In 2016The Company Is Dedicated To Developing Genetic Medicines Through Programmable Dna Editorsaiming To Create A World Free Of Disease By Shifting The Focus From Treatment To Prevention The Company Specializes In Creating Bespoke Genetic Medicines That Can Address Over 90Of The Human Genomeits Pipeline Includes Several Preclinical Treatmentsparticularly Targeting Liver And Central Nervous System Disordersone Of Its Lead Candidatesabo 101Is A Gene Editing Therapeutic For Primary Hyperoxaluria Type 1Ph1Currently In A Phase 1 2 Clinical Trial Arbor Biotechnologies Has Formed Partnerships With Key Players In The Biotechnology And Healthcare Sectorsincluding An Expanded Collaboration With Vertex And A Licensing Deal With Lonzathe Company Has Also Secured Substantial Fundingincluding A $215 Million Series B Round In 2019 And A $73 9 Million Series C Round In March 2025Reflecting Strong Investor Confidence In Its Mission And Capabilities
